A subsidiary of Johnson & Johnson has filed a New Drug Application to the Food and Drug Administration for a combination treatment for type 2 diabetes, according to a company press release.

The treatment is a combination of an experimental medication, canagliflozin, and an established drug, metformin. Combined in a pill, the treatment is intended for patients with type 2 diabetes. This is a form of the disease in which either the body doesn't respond correctly to insulin or doesn't produce enough of the substance.

The new drug has been developed by Johnson & Johnson's Janssen Research and Development subsidiary.

The article J&J Seeks Approval of Combination Diabetes Pill originally appeared on Fool.com.

Eric Volkman has no positions in Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Portfolio Basics

What are stocks? Learn how to start investing.

View Course »

What is Short Selling?

Make a profit when stocks prices fall.

View Course »

Add a Comment

*0 / 3000 Character Maximum